Paper Details

  1. Home
  2. Paper Details

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

Author: , BergThomas, ChangWen Yu, ChowWan Cheng, CooksleyGraham, FlisiakRobert, FriedMichael W, GaneEdward, LauGeorge K K, LuoKang Xian, MarcellinPatrick, McCloudPhilip, PaikSeung Woon, PiratvisuthTeerha, PluckNigel, ThongsawatSatawat

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compares the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone in treating hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
Paper Details　
Original Abstract of the Article :
Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-pos...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa043470

データ提供：米国国立医学図書館（NLM）

Peginterferon Alfa-2a and Lamivudine: A Powerful Combination for Hepatitis B

Hepatitis B is a viral infection that can cause serious liver damage. This study, published in the Journal of Hepatology, investigates the efficacy and safety of different treatment regimens for chronic hepatitis B, particularly those involving peginterferon alfa-2a and lamivudine. The authors compared the effectiveness of pegylated interferon alfa plus lamivudine, pegylated interferon alfa without lamivudine, and lamivudine alone in patients with HBeAg-positive chronic hepatitis B.

Comparing Treatment Regimens: Peginterferon Alfa-2a and Lamivudine

The study found that the combination of peginterferon alfa-2a and lamivudine was more effective than either treatment alone in achieving sustained virological response (SVR) and reducing HBeAg levels in patients with HBeAg-positive chronic hepatitis B. The authors also noted that the combination therapy was well-tolerated, with a similar safety profile to peginterferon alfa-2a alone.

Improving Treatment for Chronic Hepatitis B

The study highlights the potential of combination therapy for improving treatment outcomes in chronic hepatitis B. The findings suggest that combining peginterferon alfa-2a with lamivudine can lead to a more robust antiviral response and a higher rate of SVR, potentially preventing long-term liver damage. This approach provides a valuable treatment option for patients with chronic hepatitis B.

Dr. Camel's Conclusion

Hepatitis B can be a relentless foe, but researchers are constantly seeking new weapons to fight this disease. This study provides compelling evidence for the efficacy of combination therapy with peginterferon alfa-2a and lamivudine in treating HBeAg-positive chronic hepatitis B. Like a camel enduring a grueling journey across the desert, patients with chronic hepatitis B can benefit from effective and well-tolerated treatment options.

Date :
  1. Date Completed 2005-07-05
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

15987917

DOI: Digital Object Identifier

10.1056/NEJMoa043470

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.